Symbol | Exchange | Currency |
|---|
By Natalie Grover and Pushkala Aripaka (Reuters) -AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company...
By Pushkala Aripaka (Reuters) -AstraZeneca non-executive Chairman Leif Johansson will retire next year after serving 11 years in the role, the Anglo-Swedish drugmaker said on...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Friday, November 12th. Please refresh for updates.Johnson & Johnson (NYSE:JNJ) stock rose 2.8% after the...
Headquartered in London, AstraZeneca (NASDAQ:AZN) AZN is one of the largest biopharmaceutical companies in the world, focusing metabolic disease, cardiovascular, respiratory,...
For Immediate ReleaseChicago, IL – November 26, 2021 – Zacks Equity Research shares BJ’s Wholesale Club BJ as the Bull of the Day, and AstraZeneca (NASDAQ:AZN)...
Stock index futures were pointing to a higher open as President Joe Biden is expected to sign the infrastructure bill. Additionally, Biden is scheduled to meet with President XI...
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 92.88 | 94.48 | 92.25 | +6.40 | +7.40% | 8.82M | NYSE | |||
| 99.03 | 100.35 | 97.54 | +4.79 | +5.08% | 30.41M | NASDAQ | |||
| 25.33 | 25.44 | 24.59 | +1.03 | +4.24% | 2.21M | NYSE | |||
| 76.16 | 82.44 | 76.00 | +5.83 | +8.29% | 5.95M | NYSE | |||
| 8.23 | 8.40 | 8.20 | +0.10 | +1.23% | 1.16M | NYSE | |||
| 1.125 | 1.1667 | 1.12 | +0.0350 | +3.21% | 1.83M | NYSE | |||
| 4.67 | 4.7662 | 4.29 | +0.1700 | +3.78% | 63.75K | NASDAQ | |||
| 161.19 | 162.76 | 159.76 | +4.76 | +3.04% | 623.26K | NYSE | |||
| 10.36 | 10.37 | 10.34 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 13.79 | 13.90 | 13.77 | +0.15 | +1.10% | 1.70M | NYSE | |||
| 0.177 | 0.18 | 0.1729 | +0.0043 | +2.49% | 293.94K | NYSE | |||
| 70.42 | 70.89 | 69.19 | +2.11 | +3.09% | 215.01K | NYSE | |||
| 46.17 | 46.17 | 46.17 | +0.29 | +0.64% | 100.00 | OTC Markets | |||
| 38.05 | 38.13 | 37.64 | +0.54 | +1.43% | 1.89M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE |